Quality of life (QOL) is an important outcome for hematopoietic cell transplantation (HCT) recipients. Whether pre-HCT QOL adds prognostic information to patient and disease related risk factors has not been well described. We investigated the association of pre-HCT QOL with relapse, non-relapse mortality (NRM), and overall mortality after allogeneic HCT. From 2003 to 2012, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale instrument was administered before transplantation to 409 first allogeneic HCT recipients. We examined the association of the three outcomes with (1) individual QOL domains, (2) trial outcome index (TOI) and (3) total score. In multivariable models with individual domains, functional well-being (hazard ratio (HR) 0.95, P = 0.025) and additional concerns (HR 1.39, P = 0.002) were associated with reduced risk of relapse, no domain was associated with NRM, and better physical well-being was associated with reduced risk of overall mortality (HR 0.97, P = 0.04). TOI was not associated with relapse or NRM but was associated with reduced risk of overall mortality (HR 0.93, P = 0.05). Total score was not associated with any of the three outcomes. HCT-comorbidity index score was prognostic for greater risk of relapse and mortality but not NRM. QOL assessments, particularly physical functioning and functional well-being, may provide independent prognostic information beyond standard clinical measures in allogeneic HCT recipients. 1-12 Allogeneic hematopoietic cell transplantation (HCT) is an effective curative option for many patients with high-risk hematologic malignancies and other blood disorders. Despite advances in transplantation techniques and supportive care, the morbidity and mortality related to this intensive treatment remain high. Many factors predict survival outcomes after allogeneic HCT, including patient age, comorbidities, donor source, performance status, diagnoses, disease status, and carepartner support. Although several studies have investigated and described QOL after transplantation, including the trajectory of QOL risk factors for QOL impairments and interventions to improve QOL, 13-20 the association of pre-transplantation QOL with recovery and survival after allogeneic HCT has not been well described. We hypothesized that QOL measures before HCT may add to the prognostic information provided by known clinical factors among allogeneic HCT recipients. We therefore undertook this analysis to determine the prognostic impact of pre-transplant QOL scores, as captured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT), on post-HCT non-relapse mortality (NRM) and overall mortality.
INTRODUCTION
Patient-reported outcomes and quality of life (QOL) are becoming increasingly recognized as important factors in cancer clinical trials and patient care. Many studies have described the predictive value of QOL in cancer survival beyond standard clinical measures. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Allogeneic hematopoietic cell transplantation (HCT) is an effective curative option for many patients with high-risk hematologic malignancies and other blood disorders. Despite advances in transplantation techniques and supportive care, the morbidity and mortality related to this intensive treatment remain high. Many factors predict survival outcomes after allogeneic HCT, including patient age, comorbidities, donor source, performance status, diagnoses, disease status, and carepartner support. Although several studies have investigated and described QOL after transplantation, including the trajectory of QOL risk factors for QOL impairments and interventions to improve QOL, [13] [14] [15] [16] [17] [18] [19] [20] the association of pre-transplantation QOL with recovery and survival after allogeneic HCT has not been well described. We hypothesized that QOL measures before HCT may add to the prognostic information provided by known clinical factors among allogeneic HCT recipients. We therefore undertook this analysis to determine the prognostic impact of pre-transplant QOL scores, as captured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT), on post-HCT non-relapse mortality (NRM) and overall mortality.
PATIENTS AND METHODS Patients
Since June 2003, patients undergoing HCT at our institution have been invited to complete a detailed psychometric assessment before transplantation. In addition, our institution's transplant database prospectively collects patient-, disease-, and transplant-related data on all consecutive transplantations performed through our Blood & Marrow Transplant Program. We abstracted data on all consecutive allogeneic HCT performed between June 2003 and December 2012 for this analysis. Overall, 581 allogeneic transplantations were performed on 555 adult patients during this time period. From these 555 patients, 43 who had undergone a prior autologous or allogeneic transplant were excluded so that their baseline QOL would not be impacted by the effect of previous transplant. Prospective QOL assessment data were available for 409 of the 512 eligible patients. The study was approved by the Institutional Review Board at the Cleveland Clinic.
QOL Instruments
Baseline health-related QOL and psychosocial functioning was assessed by the FACT-BMT. 21 The FACT-BMT is a validated 37-item (including a 10-item BMT subscale) self-reported questionnaire, which includes a 10-item Bone Marrow Transplant Subscale. FACT consists of five component scores and two summary scores. The five component scores are physical well-being (PWB; range 0-28), social well-being (SWB; range 0-28), emotional wellbeing (EWB; range 0-24), functional well-being (FWB; range 0-28) and additional concerns (AC; range 0-92). One summary score is the trial outcome index (TOI; range 0-148), which is PWB+FWB+AC. TOI is considered to be more responsive to changes in physical and functional outcomes, sometimes more so than the total score that includes social and emotional well-being. The other summary score is the total score, PWB+SWB+EWB+FWB+AC (range 0-200). All scores are calculated so that higher scores represent better QOL.
was generally offered to patients older than 60 years of age and those younger than 60 years with significant comorbidities. Intensity of conditioning was defined according to the Center for International Blood and Marrow Transplant Research criteria. 22 The most common myeloablative conditioning regimens included busulfan (12.8 mg/kg i.v. or 14 mg/kg orally) and cyclophosphamide (120 mg/kg); cyclophosphamide (120 mg/kg) and 1200 cGy TBI; and etoposide (60 mg/kg) and TBI 1320 cGy. The most commonly used RIC regimen was fludarabine (90 mg/m 2 ) and TBI 400 cGy. Disease risk was defined by the American Society of Blood and Marrow Transplant request for information disease classifications. Comorbidities were scored according to the HCT-comorbidity index (HCT-CI) and severity was graded as low (score 0), intermediate (score [1] [2] and high (score ⩾ 3). 23 The HCT-CI was assigned prospectively from 2009 to 2012, and retrospectively assigned from 2002 to 2009. GvHD prophylaxis generally consisted of a calcineurin inhibitor (cyclosporine or tacrolimus), in combination with methotrexate or mycophenolate mofetil. Supportive care was provided according to standard institutional clinical guidelines as previously described. 24 
Statistical methods
The primary study aims were to evaluate the association of pre-transplant QOL scores as captured by the FACT-BMT instrument with overall mortality and NRM. To assess potential selection bias, 409 study patients were compared with 103 non-study patients who had been excluded because they failed to complete pre-transplant psychometric assessments (Supplementary Table 1 ). Baseline categorical variables were compared using the χ 2 test; continuous variables were compared using the Wilcoxon rank sum test or t-test. Outcomes were calculated from the date of transplant; patients with second transplant were censored at the time of second transplant. Overall mortality was estimated with the Kaplan-Meier method and compared with the log-rank test. All other outcomes were estimated with the cumulative incidence method and compared with the Gray test. Among the study cohort, risk factors were identified using Cox proportional hazards analysis for overall mortality, and Fine and Gray competing risk regression for NRM and relapse; analyses were adjusted for relevant clinical variables. Three separate models were obtained for the three outcomes: the first examined each of the individual FACT domains (PWB, SWB, EWB, FWB and AC), the second examined the TOI and the third examined the total score. In addition to QOL scores, univariate analysis evaluated age, gender, race, performance status, prior radiation therapy, HCT-CI score, time from diagnosis to transplant, diagnosis, disease risk, donor type, HLA-match, CMV status, conditioning regimen intensity and graft cell source. Significant or clinically important variables that were considered in all multivariate models included HCT-CI score, disease risk, HLA-match, conditioning regimen intensity, graft source and year of transplant. Of note, performance status was highly correlated with HCT-CI score and had more missing data (available in only 89% of the patients and made little change to the model with borderline significance); hence only the HCT-CI score was evaluated in multivariate models. Potential interaction between HCT-CI and QOL measures was tested, but was only found to be significant between AC and HCT-CI for relapse; hence this interaction was only included in the multivariable model for relapse. Results are summarized as hazard ratios (HRs), 95% confidence intervals (CIs) for the HR and the P-value. All analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA) and a P-value of ⩽ 0.05 was considered significant. Table 1 shows the patient, disease and transplant characteristics of the 409 patients included in this analysis. There were 211 (52%) males and 198 (48%) females with a median age of 50 years. The majority (N = 345, 95%) had a Karnofsky performance status of 80-100. Baseline HCT-CI scores were low (0) in 132 (32%), intermediate (1) (2) in 129 (32%) and high (⩾ 3) in 148 (36%) patients. The median diagnosis to transplant interval was 7 months. Most patients (N = 314, 77%) underwent a myeloablative HCT, whereas the remaining received a RIC preparative regimen (N = 95, 23%). Graft source was bone marrow in 224 (55%), peripheral blood stem cells in 142 (35%), and umbilical cord blood in 43 (10%). The QOL scores for the cohort including results Table 2 ). The mean baseline total score was 145 (s.d. 24). Median follow-up for our cohort was 49 months (range, 1-128 months). Overall mortality and NRM at 3 years was 55% and 33%, respectively. Incidence of relapse at 1 and 3 years was 24% and 29%, respectively. Relapse was the most common cause of death (23% of all deaths). Infections (19% of all deaths), followed by acute GvHD (10%) and chronic GvHD (9%), were the leading causes of NRM. Grade 2-4 and grade 3-4 acute GvHD occurred in 44% and 16% of recipients, respectively. Chronic GvHD was seen in 43% of patients. Twenty-one patients (5%) received a second transplant, and as noted in Patients and Methods, their survival was censored at the time of second transplantation.
RESULTS

Patient characteristics and outcomes
We compared the characteristics of the 409 patients with QOL data with the 103 patients who did not complete psychometric assessments before transplantation (Supplementary Materials). No significant differences were found between the study cohort and the 103 patients who did not participate in a baseline assessment during the same time period in regard to transplant outcomes or baseline characteristics, except for year of transplant, higher proportion of females and recipients of anti-thymocyte globulin as part of conditioning, and a marginally shorter time from diagnosis to transplant in the study cohort. The median follow-up (49 vs 48 months, P = 0.52), 3-year overall mortality (55% vs 54%, P = 0.80), NRM (33% vs 29%, P = 0.49) and relapse (29% vs 32%, P = 0.69) were comparable between patients with and without QOL data.
Association of baseline QOL with overall mortality, NRM and relapse Table 2 shows the results of univariate and multivariate analyses that evaluated the association of QOL with overall mortality, NRM and relapse. In univariate analysis the PWB, FWB, TOI and total scores were associated with overall mortality, although none of the individual FACT-BMT domains or aggregate scores were associated with NRM or relapse. In multivariate analyses that adjusted for patient and disease factors including the HCT-CI score, PWB scores were associated with overall mortality, but not NRM or relapse. Given this finding in the initial model, it was not unexpected that the TOI (which includes PWB) was independently associated with overall mortality. However, we did not observe an association of the total score with our outcomes of interest. FWB scores, which were not significant in univariate analysis, became significantly associated with relapse in multivariate analyses.
Additional factors were observed to be significant in multivariate analysis and were the same in all three models; these included disease risk and HCT-CI scores for overall mortality, disease risk for relapse, and graft source and year of transplant for NRM. For example, in the models that evaluated the association of FACT-BMT total score with overall mortality, in comparison to patients with low HCT-CI scores, the HR for overall mortality was 1.38 (95% CI, 0.99-1.92, P = 0.06) for patients with intermediate HCT-CI scores and 1.44 (95% CI, 1.04-2.00, P = 0.029) for patients with high HCT-CI scores. In the same analysis, compared with patients with low risk disease, the HR of overall mortality in intermediate-risk diseases was 1.02 (95% CI, 0.72-1.46, P = 0.89) and for high-risk diseases was 1.53 (95% CI, 1.13-2.08, P = 0.007). Recipients of umbilical cord blood grafts had higher risks of NRM compared with bone marrow recipients (HR 2.57; 95% CI, 1.30-5.06, P = 0.006), whereas patients receiving peripheral blood stem cell grafts had similar risks of NRM (HR 1.50; 95% CI, 0.90-2.47, P = 0.12). Patients with high-risk disease (by the ASBMT (American Society of Blood and Marrow Transplant) RFI (request for information) disease classification), relative to low-risk, had a higher risk of relapse (HR 1.97; 95% CI 1.27-3.05, P = 0.002).
DISCUSSION
Despite advances in medical therapeutics and supportive care, HCT is associated with significant morbidity and mortality risk owing to the toxicities of the conditioning regimens as well as the effects of acute and chronic GvHD and other post-transplant complications. Appropriate patient selection is important to limit the risk of adverse outcomes and identification of patients at high risk for complications is possible using screening questionnaires and tools such as the HCT-CI score. 23, 25, 26 Our study shows that pre-transplant QOL, especially domains that assess the physical and FWB of a patient, may add to the prognostic information that is provided by other risk factors for survival.
Although the association of baseline QOL with outcomes has not been well described in the HCT literature, studies focusing on this issue have been reported in patients with head and neck, esophageal, breast, lung, colorectal, cervical, bladder, renal and prostate cancers. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Systematic reviews further evaluating these findings have emphasized the prognostic significance of patientreported outcomes and QOL for survival in patients with solid cancers. 1, 27 Although the studies reviewed were heterogeneous with respect to cancer types, QOL instruments used, end points and study methodologies, some generalizations were highlighted. Most studies focused on patients with advanced solid tumors and several studies reported that the global or overall QOL was a significant independent predictor of survival. Although several measures and domains of QOL were shown to be associated with survival in this population, patient-reported outcomes of physical functioning showed particularly significant association in most studies. A meta-analysis of individual patient data from the European Organization for Research and Treatment of Cancer has shown similar results. 28 The meta-analysis included 7417 patients enrolled on 30 randomized clinical trials for 11 cancer sites for whom baseline QOL data from the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 instrument were available. QOL scales were found to provide prognostic information in addition to that of sociodemographic and clinical measures. Specifically, three QOL parameters (physical functioning, pain, and appetite loss) were found to be independent predictors of survival. A follow-up analysis from this cohort showed the predictive value of physical functioning for survival for most cancer sites, in addition to other QOL domains (for example, physical functioning, emotional functioning, global health status and nausea and vomiting were predictive in breast cancer patients, and physical functioning and pain were predictive in lung cancer patients). 29 We had hypothesized that baseline QOL would mediate survival post allogeneic HCT and we found that PWB was independently significantly associated with overall survival. PWB is a measure of patient-reported symptoms including energy, nausea, and side effects of 'feeling ill. ' We thus hypothesized that QOL would primarily mediate survival through its association with NRM. However, interestingly, we did not observe an association between QOL and NRM, and we subsequently evaluated the association between QOL and relapse. Here we did find a significant association between FWB and relapse on multivariate analyses. FWB measures parameters such as ability to return to work, acceptance of illness and ability to enjoy activities. This raises the possibility that disease burden, or correlates of this (for example, prior therapies), may also play a role or contribute to QOL assessment in regard to physical and FWB, and that patientreported QOL of this burden may provide additional prognostic information besides our standard clinical measures of disease burden, prior therapies and performance status/HCT-CI. Although there is clearly some overlap in the patient-reported measures, it is unclear why PWB was found to be significant in overall mortality but FWB was significant in relapse. Several potential limitations may also exist-despite having a sample size of 409 patients, our study still may not have enough power to detect significant associations between QOL and NRM. Furthermore, our study population was heterogeneous with respect to patient, disease and transplant characteristics. One may postulate that different diseases and their respective treatments may vary and influence patient-reported outcomes before transplantation. Because the majority of patients received myeloablative regimens and bone marrow grafts, these results may also not be as applicable The other significant variable on multivariable analysis for relapse in all three models was disease risk. A significant interaction was observed between HCT-CI score and additional concerns domain.
to patients receiving reduced-intensity regimens. Similarly, the HCT-CI, the most common tool used to predict NRM, has also been shown not to be consistently predictive across different/heterogeneous transplant populations, 30 ,31 which we also found to not be predictive of NRM in this analysis. In addition, HCT-CI scores were assigned retrospectively in a large proportion of our patients and thus may not have been as accurately assessed as if prospectively defined, and may have further impacted our results. Hence, more current studies with larger, more homogenous cohorts of transplant recipients are needed to better understand the mechanisms by which specific QOL domains may influence HCT outcomes in different diseases. Furthermore, although we found that QOL was significantly associated with survival, the magnitude of difference was small. This may again be due to some of the heterogeneity in our cohort of patients, but also due to the differences in the scale (per 1 point on the scale) of QOL measurements used (Supplementary Table 2 ).
Irrespective, several explanations for the significant association of baseline pre-transplant QOL and survival can be considered. QOL may provide more sensitive information than traditional clinical variables (for example, performance status) and may be a better marker of patient behavior as it relates to diagnosis, disease burden and treatment, and of individual characteristics such as personality style and adaptive coping strategies, which in turn may affect the disease process and outcomes. 1, 27 Furthermore, QOL may be a surrogate marker of other sociodemographic factors such as socioeconomic status and care-partner support that may mediate transplantation outcomes. 27, 32 Also, patients with lower baseline PWB may have experienced negative impact on their functioning from prior treatment regimens and may be disabled pre-transplant. Hence, baseline QOL, especially physical functioning measures, in conjunction with other measures (for example, HCT-CI) could provide additional information about the patient's ability to tolerate the physiological stresses posed by an allogeneic HCT process ranging from conditioning regimen toxicities to post-transplant events such as GvHD. Preliminary data from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902 study) also support our findings. Although different measures of QOL were used, they also demonstrated that lower pre-transplant physical health-related QOL was strongly predictive of worse survival. 33 Thus, baseline pre-transplant QOL measures may provide additional independent prognostic information in patients undergoing allogeneic HCT.
In summary, QOL assessments, particularly physical functioning, may provide independent prognostic information beyond standard clinical measures including comorbidities in allogeneic HCT recipients. Although the magnitude of difference of these measures is small, further study on how QOL may be reflected by disease burden or co-morbidities and how patient-reported outcomes and behaviors may further impact survival is warranted.
